Cargando…

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective

In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer’s disease (AD)-associated cognitive decline. This could be due to their sub-optimal design and/or deployment; alternatively, their limited efficiency could be intrinsic. Distinguishing bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volloch, Vladimir, Rits-Volloch, Sophia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357217/ https://www.ncbi.nlm.nih.gov/pubmed/37212119 http://dx.doi.org/10.3233/JAD-230164

Ejemplares similares

The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept
por: Volloch, Vladimir, et al.
Publicado: (2023)

The Amyloid Cascade Hypothesis 2.0 for Alzheimer’s Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy
por: Volloch, Vladimir, et al.
Publicado: (2023)

The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer’s Disease and for Its Potential Cure at Symptomatic Stages
por: Volloch, Vladimir, et al.
Publicado: (2022)

Principles of Design of Clinical Trials for Prevention and Treatment of Alzheimer’s Disease and Aging-Associated Cognitive Decline in the ACH2.0 Perspective: Potential Outcomes, Challenges, and Solutions
por: Volloch, Vladimir, et al.
Publicado: (2023)

Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer’s Disease
por: Volloch, Vladimir, et al.
Publicado: (2018)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
por: Frey, Gary, et al.
Publicado: (2010)

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
por: Lowe, Stephen Loucian, et al.
Publicado: (2021)

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
por: Gueorguieva, Ivelina, et al.
Publicado: (2023)

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
por: Rashad, Areeba, et al.
Publicado: (2022)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
por: Fedele, Ernesto
Publicado: (2023)

Structural basis of coreceptor recognition by HIV-1 envelope spike
por: Shaik, Md Munan, et al.
Publicado: (2018)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
por: Reitz, Christiane
Publicado: (2012)

The Pathogenesis of Alzheimer's Disease: A Reevaluation of the “Amyloid Cascade Hypothesis”
por: Armstrong, R. A.
Publicado: (2011)

Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
por: Wu, Tong, et al.
Publicado: (2022)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
por: Walton, Chaska C., et al.
Publicado: (2020)

Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome
por: Bouter, Yvonne, et al.
Publicado: (2022)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

Fleshing out the amyloid cascade hypothesis: the molecular biology of Alzheimer's disease
por: Lovestone, Simon
Publicado: (2000)

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
por: Alawode, Deborah O. T., et al.
Publicado: (2022)

Distinct conformational states of SARS-CoV-2 spike protein
por: Cai, Yongfei, et al.
Publicado: (2020)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis
por: Dong, Suzhen, et al.
Publicado: (2012)

The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
por: Ricciarelli, Roberta, et al.
Publicado: (2017)

The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?
por: Kurkinen, Markku, et al.
Publicado: (2023)

Terminal differentiation of murine erythroleukemia cells: physical stabilization of end- stage cells
por: Volloch, V, et al.
Publicado: (1982)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Fitting Contralateral Neuroanatomical Asymmetry into the Amyloid Cascade Hypothesis †
por: Arreola, Fernando, et al.
Publicado: (2022)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
por: Kametani, Fuyuki, et al.
Publicado: (2018)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
por: Wessels, Alette M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_80ikn6qu2mvs83qaev0bdbpcgs